Karim Yaqub Ibrahim, Raquel Megale Moreira, Carolina Ferreira Dos Santos, Tânia Mara Varejão Strabelli, Juliana de Cássia Belizário, Maria Isabel de Moraes Pinto, Ana Karolina Barreto Berselli Marinho, Juliana Marquezi Pereira, Liliane Saraiva de Mello, Mauricio Cesar Ando, Vitor Gabriel Lopes da Silva, Paula Keiko Sato, Marcos Alves de Lima, João Italo Dias França, Ana Paula Loch, Karina Takesaki Miyaji, Vanessa Infante, Alexander Roberto Precioso, Ana Marli Christovam Sartori
Inactivated COVID-19 vaccines data in immunocompromised individuals are scarce. This trial assessed the immunogenicity of two CoronaVac doses and additional BNT162b2 mRNA vaccine doses in immunocompromised (IC) and immunocompetent (H) individuals. Adults with solid organ transplant (SOT), hematopoietic stem cell transplant, cancer, inborn immunity errors or rheumatic diseases were included in the IC group. Immunocompetent adults were used as control group for comparison. Participants received two CoronaVac doses within a 28-day interval...
2024: Revista do Instituto de Medicina Tropical de São Paulo